The Experts below are selected from a list of 177 Experts worldwide ranked by ideXlab platform
Yaron Arbel - One of the best experts on this subject based on the ideXlab platform.
-
Forced Diuresis with matched hydration during transcatheter aortic valve implantation for Reducing Acute Kidney Injury: a randomized, sham-controlled study (REDUCE-AKI).
European heart journal, 2019Co-Authors: Yaron Arbel, Amir Halkin, Maayan Konigstein, Eyal Ben-assa, Daniela Puzhevsky, Batia Litmanowicz, Naama Galli, Ehud Chorin, Ben Sadeh, Orit Kliuk-ben BassatAbstract:Aims Acute kidney injury (AKI) is a common complication following transcatheter aortic valve implantation (TAVI) and is associated with increased risk for short- and long-term mortality. In patients undergoing percutaneous coronary intervention (PCI), Forced Diuresis with matched hydration has been shown to reduce the incidence of AKI by ∼50%. The aim of the present study was to evaluate whether Forced Diuresis with matched intravenous hydration reduces AKI in patients undergoing TAVI. Methods and results Reducing Acute Kidney Injury (REDUCE-AKI) was a single-centre, prospective, randomized, double-blind sham-controlled clinical trial, designed to examine the effect of an automated matched saline infusion with urine output for the prevention of AKI in patients undergoing TAVI. A total of 136 TAVI patients were randomized, 68 in each group. Mean age was 83.9 ± 5 years and 41.2% were males. There were no differences in baseline characteristics between the two groups. The rate of AKI was not statistically different between the groups (25% in the active group vs. 19.1% in the sham group, P = 0.408). There was a significant increase in long-term mortality in the active group (27.9% vs. 13. 2% HR 3.744, 95% CI 1.51-9.28; P = 0.004). The study was terminated prematurely by the Data Safety Monitoring Board for futility and a possible signal of harm. Conclusions Unlike in PCI, Forced Diuresis with matched hydration does not prevent AKI in patients undergoing TAVI, and might be associated with increased long-term mortality. Future studies should focus on understanding the mechanisms behind these findings. Clinicaltrials.gov registration NCT01866800, 30 April 2013.
-
Background
2014Co-Authors: Yaron Arbel, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Maayan Konigstein, Arie Steinvil, Eyal Ben-assa, Eran Leshem-rubinow, Yigal AbramowitzAbstract:Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): study protocol for a randomized sham-controlled tria
-
Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation reduce aki study protocol for a randomized sham controlled trial
Trials, 2014Co-Authors: Yaron Arbel, Eyal Benassa, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Eran Leshemrubinow, Maayan Konigstein, Arie Steinvil, Yigal AbramowitzAbstract:Background: Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced Diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI. Methods/Design: Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure. Discussion: The Reduce-AKI trial will investigate whether the use of automated Forced Diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.
-
Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation reduce aki study protocol for a randomized sham controlled trial
Trials, 2014Co-Authors: Yaron Arbel, Eyal Benassa, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Eran Leshemrubinow, Maayan Konigstein, Arie Steinvil, Yigal AbramowitzAbstract:Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced Diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI. Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure. The Reduce-AKI trial will investigate whether the use of automated Forced Diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI. Clinicaltrials.gov: NCT01866800 , 30 April 30 2013.
David Baribeault - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of the rates of cisplatin cddp induced nephrotoxicity associated with sodium loading or sodium loading with Forced Diuresis as a preventative measure
Journal of Oncology Pharmacy Practice, 2010Co-Authors: Lily Leu, David BaribeaultAbstract:Objective. To determine whether Forced Diuresis and sodium loading or sodium loading alone is better at preventing cisplatin-induced nephrotoxicity.Methods. Records of 92 patients receiving cisplat...
Orit Kliuk-ben Bassat - One of the best experts on this subject based on the ideXlab platform.
-
Forced Diuresis with matched hydration during transcatheter aortic valve implantation for Reducing Acute Kidney Injury: a randomized, sham-controlled study (REDUCE-AKI).
European heart journal, 2019Co-Authors: Yaron Arbel, Amir Halkin, Maayan Konigstein, Eyal Ben-assa, Daniela Puzhevsky, Batia Litmanowicz, Naama Galli, Ehud Chorin, Ben Sadeh, Orit Kliuk-ben BassatAbstract:Aims Acute kidney injury (AKI) is a common complication following transcatheter aortic valve implantation (TAVI) and is associated with increased risk for short- and long-term mortality. In patients undergoing percutaneous coronary intervention (PCI), Forced Diuresis with matched hydration has been shown to reduce the incidence of AKI by ∼50%. The aim of the present study was to evaluate whether Forced Diuresis with matched intravenous hydration reduces AKI in patients undergoing TAVI. Methods and results Reducing Acute Kidney Injury (REDUCE-AKI) was a single-centre, prospective, randomized, double-blind sham-controlled clinical trial, designed to examine the effect of an automated matched saline infusion with urine output for the prevention of AKI in patients undergoing TAVI. A total of 136 TAVI patients were randomized, 68 in each group. Mean age was 83.9 ± 5 years and 41.2% were males. There were no differences in baseline characteristics between the two groups. The rate of AKI was not statistically different between the groups (25% in the active group vs. 19.1% in the sham group, P = 0.408). There was a significant increase in long-term mortality in the active group (27.9% vs. 13. 2% HR 3.744, 95% CI 1.51-9.28; P = 0.004). The study was terminated prematurely by the Data Safety Monitoring Board for futility and a possible signal of harm. Conclusions Unlike in PCI, Forced Diuresis with matched hydration does not prevent AKI in patients undergoing TAVI, and might be associated with increased long-term mortality. Future studies should focus on understanding the mechanisms behind these findings. Clinicaltrials.gov registration NCT01866800, 30 April 2013.
Amir Halkin - One of the best experts on this subject based on the ideXlab platform.
-
Forced Diuresis with matched hydration during transcatheter aortic valve implantation for Reducing Acute Kidney Injury: a randomized, sham-controlled study (REDUCE-AKI).
European heart journal, 2019Co-Authors: Yaron Arbel, Amir Halkin, Maayan Konigstein, Eyal Ben-assa, Daniela Puzhevsky, Batia Litmanowicz, Naama Galli, Ehud Chorin, Ben Sadeh, Orit Kliuk-ben BassatAbstract:Aims Acute kidney injury (AKI) is a common complication following transcatheter aortic valve implantation (TAVI) and is associated with increased risk for short- and long-term mortality. In patients undergoing percutaneous coronary intervention (PCI), Forced Diuresis with matched hydration has been shown to reduce the incidence of AKI by ∼50%. The aim of the present study was to evaluate whether Forced Diuresis with matched intravenous hydration reduces AKI in patients undergoing TAVI. Methods and results Reducing Acute Kidney Injury (REDUCE-AKI) was a single-centre, prospective, randomized, double-blind sham-controlled clinical trial, designed to examine the effect of an automated matched saline infusion with urine output for the prevention of AKI in patients undergoing TAVI. A total of 136 TAVI patients were randomized, 68 in each group. Mean age was 83.9 ± 5 years and 41.2% were males. There were no differences in baseline characteristics between the two groups. The rate of AKI was not statistically different between the groups (25% in the active group vs. 19.1% in the sham group, P = 0.408). There was a significant increase in long-term mortality in the active group (27.9% vs. 13. 2% HR 3.744, 95% CI 1.51-9.28; P = 0.004). The study was terminated prematurely by the Data Safety Monitoring Board for futility and a possible signal of harm. Conclusions Unlike in PCI, Forced Diuresis with matched hydration does not prevent AKI in patients undergoing TAVI, and might be associated with increased long-term mortality. Future studies should focus on understanding the mechanisms behind these findings. Clinicaltrials.gov registration NCT01866800, 30 April 2013.
-
Background
2014Co-Authors: Yaron Arbel, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Maayan Konigstein, Arie Steinvil, Eyal Ben-assa, Eran Leshem-rubinow, Yigal AbramowitzAbstract:Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): study protocol for a randomized sham-controlled tria
-
Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation reduce aki study protocol for a randomized sham controlled trial
Trials, 2014Co-Authors: Yaron Arbel, Eyal Benassa, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Eran Leshemrubinow, Maayan Konigstein, Arie Steinvil, Yigal AbramowitzAbstract:Background: Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced Diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI. Methods/Design: Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure. Discussion: The Reduce-AKI trial will investigate whether the use of automated Forced Diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.
-
Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation reduce aki study protocol for a randomized sham controlled trial
Trials, 2014Co-Authors: Yaron Arbel, Eyal Benassa, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Eran Leshemrubinow, Maayan Konigstein, Arie Steinvil, Yigal AbramowitzAbstract:Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced Diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI. Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure. The Reduce-AKI trial will investigate whether the use of automated Forced Diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI. Clinicaltrials.gov: NCT01866800 , 30 April 30 2013.
Maayan Konigstein - One of the best experts on this subject based on the ideXlab platform.
-
Forced Diuresis with matched hydration during transcatheter aortic valve implantation for Reducing Acute Kidney Injury: a randomized, sham-controlled study (REDUCE-AKI).
European heart journal, 2019Co-Authors: Yaron Arbel, Amir Halkin, Maayan Konigstein, Eyal Ben-assa, Daniela Puzhevsky, Batia Litmanowicz, Naama Galli, Ehud Chorin, Ben Sadeh, Orit Kliuk-ben BassatAbstract:Aims Acute kidney injury (AKI) is a common complication following transcatheter aortic valve implantation (TAVI) and is associated with increased risk for short- and long-term mortality. In patients undergoing percutaneous coronary intervention (PCI), Forced Diuresis with matched hydration has been shown to reduce the incidence of AKI by ∼50%. The aim of the present study was to evaluate whether Forced Diuresis with matched intravenous hydration reduces AKI in patients undergoing TAVI. Methods and results Reducing Acute Kidney Injury (REDUCE-AKI) was a single-centre, prospective, randomized, double-blind sham-controlled clinical trial, designed to examine the effect of an automated matched saline infusion with urine output for the prevention of AKI in patients undergoing TAVI. A total of 136 TAVI patients were randomized, 68 in each group. Mean age was 83.9 ± 5 years and 41.2% were males. There were no differences in baseline characteristics between the two groups. The rate of AKI was not statistically different between the groups (25% in the active group vs. 19.1% in the sham group, P = 0.408). There was a significant increase in long-term mortality in the active group (27.9% vs. 13. 2% HR 3.744, 95% CI 1.51-9.28; P = 0.004). The study was terminated prematurely by the Data Safety Monitoring Board for futility and a possible signal of harm. Conclusions Unlike in PCI, Forced Diuresis with matched hydration does not prevent AKI in patients undergoing TAVI, and might be associated with increased long-term mortality. Future studies should focus on understanding the mechanisms behind these findings. Clinicaltrials.gov registration NCT01866800, 30 April 2013.
-
Background
2014Co-Authors: Yaron Arbel, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Maayan Konigstein, Arie Steinvil, Eyal Ben-assa, Eran Leshem-rubinow, Yigal AbramowitzAbstract:Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): study protocol for a randomized sham-controlled tria
-
Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation reduce aki study protocol for a randomized sham controlled trial
Trials, 2014Co-Authors: Yaron Arbel, Eyal Benassa, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Eran Leshemrubinow, Maayan Konigstein, Arie Steinvil, Yigal AbramowitzAbstract:Background: Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced Diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI. Methods/Design: Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure. Discussion: The Reduce-AKI trial will investigate whether the use of automated Forced Diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.
-
Forced Diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation reduce aki study protocol for a randomized sham controlled trial
Trials, 2014Co-Authors: Yaron Arbel, Eyal Benassa, Amir Halkin, Gad Keren, Arie Lorin Schwartz, Ofer Havakuk, Eran Leshemrubinow, Maayan Konigstein, Arie Steinvil, Yigal AbramowitzAbstract:Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced Diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI. Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure. The Reduce-AKI trial will investigate whether the use of automated Forced Diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI. Clinicaltrials.gov: NCT01866800 , 30 April 30 2013.